Sir Peter MacCallum Department of Oncology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/274

Filters

2019 - 2020 4
3 1
Reset filters

Settings
Statistics
Citations
Author: Westerman, David × Author: Blombery, Piers × End date: 2020 ×

Search Results

Now showing 1 - 4 of 4
  • Item
    Thumbnail Image
    Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
    Blombery, P ; Birkinshaw, RW ; Nguyen, T ; Gong, J-N ; Thompson, ER ; Xu, Z ; Westerman, DA ; Czabotar, PE ; Dickinson, M ; Huang, DCS ; Seymour, JF ; Roberts, AW (WILEY, 2019-09)
  • Item
    No Preview Available
    Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications
    Kuzich, JA ; Kankanige, Y ; Guinto, J ; Ryland, G ; McBean, M ; Thompson, E ; Wong, E ; Koldej, R ; Collins, J ; Westerman, D ; Ritchie, DS ; Blombery, P (ELSEVIER SCIENCE INC, 2020-03)
  • Item
    Thumbnail Image
    Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia
    Ryland, GL ; Barraclough, A ; Fong, CY ; Fleming, S ; Bajel, A ; Hofmann, O ; Westerman, D ; Grimmond, S ; Blombery, P (WILEY, 2020-10)
  • Item
    No Preview Available
    Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
    Lew, TE ; Anderson, MA ; Lin, VS ; Handunnetti, SM ; Came, NA ; Blombery, P ; Westerman, DA ; Wall, M ; Tam, CS ; Roberts, AW ; Seymour, JF (ELSEVIER, 2020-01-14)
    The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), including undetectable minimal residual disease (uMRD). We retrospectively reviewed 62 patients with CLL treated with venetoclax to investigate the performance of peripheral blood (PB) compared with bone marrow (BM) assessment of MRD; the kinetics, clinicopathological associations, and longer-term outcomes of uMRD attainment and recrudescence; and the ability of venetoclax dose escalation to deepen responses. Among 16 patients who achieved PB uMRD and had contemporaneous BM assessments, 13 (81%) had confirmed BM uMRD, and patients with PB uMRD had outcomes at least as favorable as those with BM uMRD for time to progression, overall survival, and MRD recrudescence. Excluding 2 patients lacking earlier assessment, the median time to PB uMRD was 18 (range, 5-26) months, with 90% of instances achieved by 24 months. There was no new PB uMRD attainment after 24 months without treatment intensification. The dominant association with earlier attainment of uMRD was concurrent rituximab (P = .012). Complex karyotype was associated with inferior uMRD attainment after 12 months of therapy (P = .015), and patients attaining uMRD whose disease harbored TP53 abnormalities demonstrated a trend toward earlier recrudescence (P = .089). Of patients who received venetoclax dose escalations, 4 (27%) of 15 achieved improvements in response. For patients with R/R CLL receiving venetoclax, PB uMRD commonly correlates with BM uMRD and is associated with a comparable longer-term prognosis. Concurrent rituximab augments uMRD attainment, but dose escalation and further treatment beyond 24 months infrequently deepen responses.